Clinical Protocol to Investigate the Efficacy of Amlexanox vs. Placebo for Treatment of Glucose and Lipid Abnormalities in Obese Type 2 Diabetics
Phase of Trial: Phase II
Latest Information Update: 16 Nov 2018
Price : $35 *
At a glance
- Drugs Amlexanox (Primary)
- Indications Non-alcoholic fatty liver disease; Obesity; Type 2 diabetes mellitus
- Focus Biomarker; Pharmacodynamics
- 08 Oct 2018 Status changed from active, no longer recruiting to completed.
- 31 Aug 2018 Biomarkers information updated
- 31 Oct 2017 Planned End Date changed from 1 Oct 2016 to 1 Dec 2019.